Glioblastoma is the most common and aggressive primary malignant brain tumour. Due to the lack of effective treatment options, Cancer Research UK has included glioblastoma in the category of ‘cancers of substantial unmet need’. Our goal is to improve clinical outcomes for patients with glioblastoma, from pre-clinical development of novel therapies to early and later phase clinical trials.
We have set up a national programme of clinical trials for patients with glioblastoma. Currently we are completing recruitment for the IPI-GLIO trial (ISRCTN84434175) which is a phase II, open label, randomized study of ipilimumab (anti-CTLA monoclonal antibody) and temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma. We are currently establishing a platform study of neo-adjuvant therapies (NeAT) for patients with glioblastoma.
Molecular mechanisms in glioblastoma
Alongside clinical trials, we are running a translational programme to improve our understanding of the molecular mechanisms driving glioblastoma response and resistance to treatment. There is emerging evidence that DNA organisation is critical in mediating responses to cancer treatment including chemotherapy and immunotherapy. We are characterising the DNA architecture in glioblastoma and how it can be modified to enhance treatment efficacy.
Brain Tumour Awareness Month takes place from 1st to 31st March 2021.
If you would like further information about immunotherapy and new treatment for glioblastoma, Dr Mulholland can be contacted via his Queen Square private medical secretary Sharon Sulley at email@example.com or on 020 3448 3781.